Xiangfeng He

589 citations
24 papers · 448 indexed · h-index 13
Topics
Immunotherapy and Immune Responses (6 papers)Cancer Cells and Metastasis (4 papers)Cancer-related molecular mechanisms research (4 papers)
Partner nations
ChinaLebanonBangladesh

In The Last Decade

Xiangfeng He

23 papers receiving 442 citations

Peers

Xiangfeng He
Comparison fields: 5 of 106
  • Molecular Biology 231
  • Oncology 148
  • Cancer Research 144
  • Immunology 90
  • Epidemiology 56
Replace D Baban with:
D Baban United Kingdom
Junsong Chen China
Shuhua Zheng United States
Zhilan Zeng United States
Zhenqing Feng China
Liangpeng Yang United States
Philaretos C. Kousis United States
Eman A. Taha Japan
Lan Fang China
Immacolata Longanesi-Cattani Italy
Xiangfeng He relative to D Baban United Kingdom D Baban's profile →
Citations per field
00.5×3.3×
D Baban · 1×
Citations per year

Countries citing papers authored by Xiangfeng He

Since Specialization
Citations

This map shows the geographic impact of Xiangfeng He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiangfeng He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiangfeng He more than expected).

Fields of papers citing papers by Xiangfeng He

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiangfeng He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiangfeng He. The network helps show where Xiangfeng He may publish in the future.

Co-authorship network of co-authors of Xiangfeng He

This figure shows the co-authorship network connecting the top 25 collaborators of Xiangfeng He. A scholar is included among the top collaborators of Xiangfeng He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiangfeng He. Xiangfeng He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 6
4 9
5 16
6 3
7 6
8 11
9
MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2.
29
10 24
11 28
12 20
13 3
14 10
15 15
16 43
17 25
18 49
19 33
20 1

About Xiangfeng He

Xiangfeng He is a scholar working on Conservation, Cancer Research and Immunology, having authored 24 papers that have together received 448 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (6 papers), Cancer Cells and Metastasis (4 papers) and Cancer-related molecular mechanisms research (4 papers). The work is most often cited by research in Cancer Research (144 citations), Oncology (148 citations) and Immunology (90 citations). Xiangfeng He has collaborated with scholars based in China, Lebanon and Bangladesh. Frequent co-authors include Jun Dou, Ning Gu, Fengshu Zhao, Di Wu, Miao Li, Fangfang Shi, Mei Guo, Weihua Hu, Rong Zhang and Chunsheng Liu. Their work appears in journals such as Vaccine, Environmental Research and Journal of Nanoparticle Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026